CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Cash flows from operating activities:
Net loss	$ (107,150)	$ (38,531)	$ (28,354)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	15,844	6,463	6,275
Credit losses on accounts receivable	628	588	336
Accretion of marketable securities	(2,078)	(6,833)	(1,964)
Operating lease right-of-use asset amortization	3,081	1,893	2,015
Stock-based compensation expense	20,718	19,987	16,823
Impairment	7,752	0	1,361
Change in fair value of contingent liabilities	(4,547)	0	0
Recognition of off-market liability	(2,726)	0	0
Deferred taxes	(5,867)	(290)	(290)
Other operating activity	(540)	345	140
Changes in assets and liabilities:
Accounts receivable	10,609	(7,704)	(6,695)
Inventory	4,033	(6,679)	(8,944)
Prepaid expenses and other current assets	3,521	(443)	(2,371)
Other non-current assets	252	(1,215)	(717)
Accounts payable	(528)	723	1,189
Accrued compensation and benefits, accrued expenses, and other current liabilities	(7,914)	1,398	4,410
Net change in other operating assets and liabilities	(12,324)	(4,866)	(2,063)
Net cash used in operating activities	(77,236)	(35,164)	(18,849)
Cash flows from investing activities:
Purchases of marketable debt securities	(69,757)	(295,606)	(175,613)
Proceeds from sales and maturities of marketable securities	215,829	216,709	31,000
Purchases of property and equipment	(2,612)	(3,368)	(3,841)
Acquisitions, net of cash acquired	(93,229)	0	0
Net cash provided by (used in) investing activities	50,231	(82,265)	(148,454)
Cash flows from financing activities:
Proceeds from common stock issued under stock plans	738	3,066	2,889
Payments for employee taxes withheld on stock-based compensation awards	(1,446)	(2,610)	(198)
Net cash provided by (used in) financing activities	(708)	456	2,691
Net decrease in cash, cash equivalents, and restricted cash	(27,713)	(116,973)	(164,612)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	1,574	(734)	301
Cash, cash equivalents, and restricted cash at beginning of period	59,319	177,026	341,337
Cash, cash equivalents, and restricted cash at end of period	33,180	59,319	177,026
Supplemental disclosure of cash flow information:
Common stock issued in exchange for acquisition of Akoya	49,900	0	0
Purchases of property and equipment in accounts payable and accruals	$ 121	$ 1,230	$ 419